Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light

Exclusion Criteria

• •1. Any previous vaccination/immunization (within 30 days before the enrollment) and any planned vaccination within 30 days after enrollment
• •2. Any previous or planning COVID-19 vaccination with any other Regulatory approved vaccine
• •3. Positive SARS-CoV-2 screening result obtained by PCR (at screening)
• •4. Administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment
• •5. Pregnancy or lactation
• •6. Acute coronary syndrome or stroke suffered less than one year before study enrollment
• •7. Tuberculosis, chronic systemic infections associated with Immunocompromised subjects in medical history
• •8. History of severe allergic reaction to drug or vaccine (anaphylactic shock, Quincke's edema, and other life-threatening allergic reactions), acute exacerbation of allergic diseases on screening and vaccination day
• •9. Chronic autoimmune disease and system collagenases in medical history
• •10. Organ transplantation and immunosuppressive therapy
• •11. Immunosuppressive therapy and corticosteroid system therapy within 3 months before the enrollment
• •12. Subjects with malignant neoplasms within 5 years before the enrollment
• •13. Splenectomy in the past medical history
• •14. Neutropenia (absolute neutrophil count \<1,000 mm3 agranulocytosis, significant blood loss, severe anemia (hemoglobin \<80 g/L), immunodeficient disease in the medical history within 6 months before the enrollment
• •15. The active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis B, or C
• •16. Acute Kidney injury or dialysis
• •17. Anorexia or dysnutrition
• •18. Tattoos at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the vaccine/placebo
• •19. Alcohol or Drug abuse in medical history
• •20. Participation in other interventional clinical trial within the previous 90 days prior to vaccination and over duration of the trial
• •21. Any other condition that the investigator considers as a barrier to the trial completion as per the protocol